Impact of Walking on Adipose Tissue Lipoprotein Lipase Activity and Expression in Pre- and Postmenopausal Women

Sebastien Tessier, Éléonor Riesco, Michel Lacaille, Francine Pérusse, John Weisnagel, Jean Doré, Pascale Mauriège

a Division of Kinesiology, Laval University, b Laval Hospital Research Center, Québec City, QC, c Research Center on Aging, IUGS, Sherbrooke, QC, d Diabetes Research Unit, CHUL Research Center, Québec City, QC, Canada

Keywords
Lipid storage · Menopause · Obesity · Exercise · Metabolic profile

Summary
Objective: The aim of this study was to examine regional variation in adipose tissue lipoprotein lipase (AT-LPL) activity and expression in pre- and postmenopausal women, before and after training, once differences in chronological age or obesity degree are taken into account.

Methods: Sixteen late pre- and 14 early postmenopausal (49 ± 2 vs. 52 ± 2 years; p < 0.001) moderately obese women (body mass index 29–35 kg/m²) were subjected to a 16-week walking program (3 sessions/week of 45 min at 60% heart rate reserve). Abdominal and femoral AT-LPL activity and expression, fasting lipid-lipoprotein profile, body composition, and cardiorespiratory fitness (CRF) were measured before and after our intervention. Statistical analyses were performed using covariance analysis for age differences.

Results: AT-LPL activity and expression, lipid-lipoprotein metabolism, body fatness, and CRF were similar at baseline, irrespective of the group considered. Slight reductions in plasma cholesterol and high-density lipoprotein (HDL) cholesterol levels, fat mass and waist girth reductions, CRF increases as well as femoral AT-LPL activity and expression decreases after our intervention were comparable, regardless of menopausal status (0.0001 < p < 0.05).

Conclusions: Lipid storage is decreased in the femoral depot after walking, regardless of menopausal status. Reduction in AT-LPL activity or expression does not lead to a more deleterious lipid-lipoprotein profile, despite the modest decrease noted in HDL cholesterol concentrations.

Introduction
Numerous studies have already pointed out that premenopausal women tend to accumulate excess fat predominantly in the gluteo-femoral areas which may, to a certain extent, be cardioprotective, while postmenopausal women display a preferential abdominal fat deposition associated with an increased risk of metabolic complications [1, 2]. In this regard, regional variation in adipose tissue lipoprotein lipase (AT-LPL) activity, a key regulator of lipid storage [3], has already been hypothesized to account for differences in body fat distribution occurring during the transition to menopause [4]. Indeed, AT-LPL activity is higher in the gluteo-femoral than in the abdominal region in premenopausal women [5–8], although discordant results concerning the presence [6, 9] or absence of regional variation in this enzyme activity were reported in postmenopausal women [7, 10, 11]. Main reasons for these conflicting data could be i) the lack of clear identification of women being in their perimenopausal phase [9], ii) that premenopausal women were examined in the luteal phase [6] or at any point of their menstrual cycle [7], iii) the use or not of hor-
mone therapy (HT) by women at menopause [7, 11–13], and iv) that pre- and postmenopausal women studied were not matched for age, adiposity, and regional fat distribution [6, 7]. The existence of site differences in AT-LPL mRNA levels has also been documented in pre- [5, 14] but not in postmenopausal women. However, the regulatory effects of ovarian hormone deficiency on regional variation in AT-LPL activity and/or expression has never been investigated, once differences in women’s chronological age and/or obesity degree are taken into account.

On the other hand, previous studies that assessed the impact of different weight loss strategies including surgery, hypocaloric diet alone or combined with drugs or aerobic exercise on AT-LPL activity, have shown either a decrease [15] or a lack of change [10, 16, 17], whereas others have observed an increase in the enzyme activity [18–20]. Very little information on the effect of aerobic exercise alone on AT-LPL activity is, however, available with the exception of one study [21] which clearly reported a decrease in this enzyme activity at both the abdominal and femoral sites, after 6 months of endurance exercise, in obese premenopausal women. As LPL plays an important role in lipoprotein metabolism by catalyzing chylomicrons and very-low-density lipoprotein (VLDL) thus leading to the formation of high-density lipoprotein (HDL) cholesterol particles [22], we wondered whether changes in this enzyme activity and/or expression could have an impact on lipid-lipoprotein metabolism. However, the impact of a physical activity different from a standardized laboratory exercise on regional variation in AT-LPL activity and/or expression has not yet been investigated in pre- and postmenopausal women carefully matched for age and obesity degree.

Primary aims of this study were thus i) to verify whether regional variations in both AT-LPL activity and expression persist at early menopause when compared to late premenopausal status, once age and obesity degree differences are taken into account, and ii) to evaluate the impact of a 16-week walking program on AT-LPL activity and mRNA level. A secondary objective was to examine whether changes in the enzyme activity and/or expression were related to a more favourable or deleterious lipid-lipoprotein profile.

Material and Methods

Subjects

Healthy Caucasian women were recruited from the suburbs of Québec City to participate in a 16-week walking program, the Menopause Obesity and Exercise study (MenOEx), through an announcement in local newspapers. From a total of 48 women who responded, 35 participants met the following inclusion criteria: None of the women had identified cardiomyopathy, endocrine disorders which may have caused irregular menstrual cycles, or orthopaedic limitations that would affect physical activity. They had to be non-smokers and moderate consumers of alcohol and caffeine. Their body weight had to be stable (less than 2 kg weight change) in the year before the onset of the study. All participants also had to be sedentary (exercising less than 30 min per week), and moderately obese (body mass index (BMI) ranging from 29 to 35 kg/m²). Women on medication that could potentially influence the outcome of this study (β-blockers, sympathomimetics, cholesterol-lowering drugs including statins, corticosteroids, anti-hypertensive drugs, and thyrroxine for which a dosage change occurred during the last 6 months) were excluded from the present study. Premenopausal status was defined as the occurrence of 2 menses in the 3 last months, the absence of cycle irregularity in the 12 months preceding testing, mean cycle length of 24–30 days, and plasma follicle-stimulating hormone (FSH) levels lower than 30–40 IU/l. In this regard, all premenopausal women from the present study had plasma FSH levels lower than 40 IU/l. In addition, postmenopausal status was defined by amenorrhea for at least 12 months but no longer than 5 years, and plasma FSH levels greater than 30–40 IU/l (North American Menopause Society, 2000). In this regard, Henrich et al. [23] have already shown the existence of a considerable overlap among distributions of FSH by stage on a representative sample of 576 US women aged 35–60 years examined during the National Health and Nutrition Examination Survey (NHANES) 1999–2000. Indeed, FSH cut-off points between the reproductive and menopausal transition stages as well as between the menopause transition and postmenopausal stages were neither sensitive nor very specific, thus emphasizing that FSH levels had limited utility in discriminating among women in different stages. Although the physiological and clinical manifestations of transition to menopause are still not well understood, perimenopause, a time of menstrual irregularity lasting between 2 and 8 years [24–26], seems to occur in stages. During perimenopause, FSH concentrations may raise to the postmenopausal range during some cycles, but return to premenopausal levels during subsequent cycles. As FSH levels also fluctuate from month to month during this phase [24, 25], the perimenopausal status cannot thus be clearly established. It is the reason why perimenopausal women with irregular menses were excluded from our study. According to the Stages of Reproductive Aging Workshop (STRAW), late premenopausal (e.g. reproductive) stage refers to women with regular menstrual cycles associated with either normal or slightly increased plasma FSH levels [27]. Finally, premenopausal women using oral contraceptives and postmenopausal women on HT were excluded from the present study (table 1).

Study Design

The experimental design was approved by the University Ethical Committee on Human Research for Medical Sciences, and all participants gave their written informed consent to participate in this study, conformed to the Laval University Medical Ethics Committee. Before entering our protocol, all women had a physical examination which included a resting electrocardiogram, by our physicians. The exercise program was planned according to the American College of Sports and Medicine recommendations [28], and consisted of 3 non-consecutive sessions/week of 45 min walking in indoor community facilities (PEPS), at approximately 60% of heart rate (HR) reserve (HRR) (e.g. the maximal HR minus the resting HR), during 16 weeks. Maximal HR was calculated from the following equation: 220 – age, where age is expressed in years. Walking HR was calculated as percentage HRR + resting HR, according to Karlson et al. [29]. The 3-weekly walking sessions were supervised by an exercise leader. From the 35 women (18 pre- and 17 postmenopausal) who began the endurance exercise program, 16 late premenopausal women, 49 ± 2 years old (mean ± standard deviation, SD), and 14 early postmenopausal women 52 ± 2 years old completed our study and had the pre- and post-intervention fat biopsies. Reasons for drop out of 2 pre- and 3 postmenopausal women were illness (n = 1), re-location (n = 1), or wish to perform more exercise than the 3 sessions/week planned (n = 3).

Adipose Tissue Biopsy Procedure and Lipoprotein Lipase Activity

After an overnight fast, participants were subjected to biopsies of subcutaneous fat, one performed in the periumbilical region (abdominal site) and the other at the anterior midhigh level (femoral site). Local anaesthesia (1% xylocaine, without epinephrine) was performed in such a way that it...
did not influence the metabolic activity of excised adipose tissue (AT) [30]. Biopsies were performed before and 2–4 weeks after the end of the training period. All women had to remain inactive for 36 h to avoid acute effect of exercise on AT metabolism before our post-intervention [31]. For premenopausal women, biopsies were performed while they were in the follicular phase of their menstrual cycle (e.g. between the 5th and the 12th days of their menstrual cycle). Approximately 100 mg of AT from each region were immediately frozen in liquid nitrogen for later measurement of heparin-releasable lipoprotein lipase (LPL) activity, according to Imbeault et al. [5], and all experiments were run in duplicates [32,33].

**Table 1. The STRAW staging system [27]**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Terminology</th>
<th>Duration of Stage</th>
<th>Menstrual Cycles</th>
<th>Endocrine</th>
<th>Final Menstrual Period (FMP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-5</td>
<td>Reproductive</td>
<td>variable</td>
<td>variable</td>
<td>normal FSH</td>
<td>0</td>
</tr>
<tr>
<td>-4</td>
<td>Reproductive</td>
<td>variable</td>
<td>regular</td>
<td>↑ FSH</td>
<td>+1</td>
</tr>
<tr>
<td>-3</td>
<td>Menopausal Transition</td>
<td>variable cycle length (&gt;7 days different from normal)</td>
<td>variable</td>
<td>↑ FSH</td>
<td>+2</td>
</tr>
<tr>
<td>-2</td>
<td>Menopausal Transition</td>
<td>≥2 skipped cycles and an interval of amenorrhea (260 days)</td>
<td>≥2 skipped cycles and an interval of amenorrhea (260 days)</td>
<td>↑ FSH</td>
<td>+1</td>
</tr>
<tr>
<td>-1</td>
<td>Perimenopause</td>
<td>1 yr</td>
<td>regular</td>
<td>↑ FSH</td>
<td>+1</td>
</tr>
<tr>
<td>0</td>
<td>Perimenopause</td>
<td>4 yrs</td>
<td>regular</td>
<td>↑ FSH</td>
<td>+1</td>
</tr>
<tr>
<td>+1</td>
<td>Perimenopause</td>
<td>until demise</td>
<td>regular</td>
<td>↑ FSH</td>
<td>+1</td>
</tr>
<tr>
<td>+2</td>
<td>Perimenopause</td>
<td>none</td>
<td>variable</td>
<td>↑ FSH</td>
<td>+1</td>
</tr>
</tbody>
</table>

*Stages most likely to be characterized by vasomotor symptoms*  
↑ = elevated

**Cardiorespiratory Fitness**

Cardiorespiratory fitness (CRF) was assessed by the 2-km walking test which was validated on moderately fit and obese but otherwise healthy men and women 20-65 years old [37]. Estimated maximal oxygen uptake \( V\dot{O}_2\text{max} \) (ml/kg/min) was calculated based on sex-specific prediction models which included walking time, HR at the end of the walk, age, and BMI. Equation used to predict \( V\dot{O}_2\text{max} \) in women was the following:

\[
V\dot{O}_2\text{max}(\text{ml/kg/min}) = 116.2 - 2.98 \times \text{time} - 0.11 \times \text{HR} - 0.14 \times \text{age} - 0.39 \times \text{BMI, where time is the elapsed time for a walk in minutes, HR is the value at the end of the walk (beats/min), age is expressed in years and BMI in kg/m}^2.
\]

**Plasma Determinations**

Blood was collected from an antecubital vein in the morning after a 12-hour overnight fast and a 15-min rest period, and plasma samples were stored at -80°C until use. Women had to remain inactive for 36 h to eliminate any acute effect of exercise on the metabolic profile before our post-intervention [51]. Fasting total cholesterol, triacylglycerol (TAG) and HDL cholesterol levels were determined according to standardized laboratory procedures on a Technicon RA-500 analyzer (Bayer, Tarrytown, NJ, USA). Apolipoprotein B was measured by nephelometry (BN ProSpec; Dade Behring, Newark, DE, USA) with reagents provided by this company (N Antiser to Human Apolipoprotein B). Fasting low-density lipoprotein (LDL) cholesterol concentrations were estimated using the Friedewald equation [38]. Plasma FSH concentrations were determined by a radioimmunoassay kit (Diagnostic System Laboratories, Webster, TX, USA) while estradiol levels were measured by a competitive immunological assay (Immuno-1 apparatus, Bayer). Fasting blood sample measurements were performed irrespective of premenopausal women’s menstrual cycle.
Table 2. Subjects’ physical characteristics before and after our walking program (means ± SD)

<table>
<thead>
<tr>
<th></th>
<th>Premenopausal women (n = 16)</th>
<th>Postmenopausal women (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>before</td>
<td>after</td>
</tr>
<tr>
<td>Age, years</td>
<td>49.0 ± 2.06</td>
<td>52.0 ± 2.0</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>81.9 ± 9.8</td>
<td>79.9 ± 10.21</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>31.9 ± 3.0</td>
<td>31.1 ± 3.2</td>
</tr>
<tr>
<td>Waist girth, cm</td>
<td>97.8 ± 8.8</td>
<td>95.2 ± 9.5</td>
</tr>
<tr>
<td>Fat mass, kg</td>
<td>35.3 ± 6.6</td>
<td>33.8 ± 6.66</td>
</tr>
<tr>
<td>Lean mass, kg</td>
<td>46.6 ± 4.4</td>
<td>46.1 ± 4.5</td>
</tr>
<tr>
<td>VO₂ max, ml/kg/min</td>
<td>20.2 ± 5.4</td>
<td>24.1 ± 4.8</td>
</tr>
<tr>
<td>Regional fat cell weight, μg lipid/cell</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal</td>
<td>0.64 ± 0.17</td>
<td>0.69 ± 0.17</td>
</tr>
<tr>
<td>Femoral</td>
<td>0.77 ± 0.37</td>
<td>0.62 ± 0.14</td>
</tr>
</tbody>
</table>

*p < 0.001: significant difference between pre- and postmenopausal women at baseline.  
*p < 0.05; *p < 0.01; *p < 0.001; *p < 0.0001: significant difference before and after walking, after adjustment for age.

Table 3. Subjects’ hormonal and lipid-lipoprotein profiles before and after our walking program (means ± SD)

<table>
<thead>
<tr>
<th></th>
<th>Premenopausal women (n = 16)</th>
<th>Postmenopausal women (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>before</td>
<td>after</td>
</tr>
<tr>
<td>FSH, IU/l</td>
<td>12.82 ± 18.72</td>
<td>16.67 ± 15.13</td>
</tr>
<tr>
<td>Estradiol, pmol/l</td>
<td>424.47 ± 317.25c</td>
<td>551.40 ± 396.08</td>
</tr>
<tr>
<td>Triacylglycerol, mmol/l</td>
<td>1.14 ± 0.59</td>
<td>1.25 ± 0.69</td>
</tr>
<tr>
<td>Cholesterol, mmol/l</td>
<td>5.28 ± 1.07</td>
<td>4.72 ± 1.07</td>
</tr>
<tr>
<td>LDL cholesterol, mmol/l</td>
<td>3.33 ± 0.92</td>
<td>2.98 ± 0.65c</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/l</td>
<td>1.41 ± 0.29c</td>
<td>1.35 ± 0.28c</td>
</tr>
<tr>
<td>CHOL/HDL cholesterol</td>
<td>3.86 ± 1.05</td>
<td>3.74 ± 0.77</td>
</tr>
<tr>
<td>Apolipoprotein B, g/l</td>
<td>0.98 ± 0.20</td>
<td>0.99 ± 0.17</td>
</tr>
</tbody>
</table>

FSH = Follicle stimulating hormone; LDL = low-density lipoprotein; HDL = high-density lipoprotein; CHOL = cholesterol.  
*p < 0.0001; *p < 0.01; significant difference between pre- and postmenopausal women at baseline, after adjustment for age.  
*p < 0.05: significant difference before and after walking, after adjustment for age.

Statistical Analyses
Results are given as means ± standard error (SE) in figures and as means ± standard deviation (SD) in tables. Complete data were recorded on 30 participants (16 late pre- and 14 early postmenopausal women) through our study. Comparison of AT-LPL activity and expression, body composition, CRF, and lipid-lipoprotein profile before and after walking was performed with a one-way (e.g. pre- vs. postmenopausal status) or a two-way covariance analysis (ANCOVA) with repeated measures and age as a covariable, using the general linear model procedure. Finally, relationships between variables were quantified using Pearson’s product moment correlation coefficients. All analyses were conducted with the SAS statistical computer program package (SAS Institute, Cary, NC, USA). Statistical significance was set at p < 0.05.

Results

Subjects’ Characteristics
As shown in table 2, comparison between groups did not reveal any difference in anthropometry, body composition, estimated VO₂ max, and regional fat cell weight, at baseline (0.18 < p < 0.98). As expected, total adiposity was reduced after training, in both groups. Body weight loss of ~2.0 ± 2.2 versus 0.6 ± 1.1 kg (means ± SD) and BMI decrease of ~0.8 ± 0.9 kg/m² versus ~0.3 ± 0.4 kg/m² were higher in pre- than in postmenopausal women, respectively (0.005 < p < 0.05). Although fat mass loss was comparable (p < 0.001), lean mass remained unchanged after walking, in both groups (p = 0.79). Waist girth was similarly reduced after our intervention, in all women (p < 0.0001). Finally, subcutaneous abdominal and femoral fat cell weight did not change in response to endurance exercise, regardless of menopausal status (0.40 < p < 0.52).

Subjects’ Hormonal and Lipid-Lipoprotein Profiles
As illustrated in table 3, plasma FSH and estradiol levels were obviously different between pre- and postmenopausal women (0.0001 < p < 0.01). With the exception of plasma HDL cholesterol concentrations being slightly lower in pre- than in postmenopausal women (p < 0.01) at baseline, the lipid-lipoprotein profile was comparable (0.17 < p < 0.71). Fasting plasma cho-
Figure 1. Adipose tissue lipoprotein lipase (AT-LPL) activity expressed either per adipose tissue mass (A), per cell number (B) or corrected for variation in adipocyte surface area (C) in subcutaneous abdominal and femoral regions of pre- (■) and postmenopausal (▲) women, before and after walking. Values are means ± S.E. § Indicates significant differences within each group, before and after walking at p < 0.005 and at p < 0.05, respectively.

Walking and Lipid Storage in Obese Women

Adipose Tissue-Lipoprotein Lipase Activity and Expression
Figure 1 illustrates the effect of our walking program on AT-LPL activity expressed either per AT mass, per cell number, or corrected for variation in cell surface area, in subcutaneous abdominal and femoral adipose regions of pre- and postmenopausal women. No regional variation was found in the initial AT-LPL activity, regardless of data expression and menopausal status (0.08 < p < 0.88). A decrease in femoral AT-LPL activity when expressed per AT mass or cell number was observed in response to our intervention, in both groups (0.005 < p < 0.05). However, this enzyme activity measured in the abdominal fat depot did not change after walking, in both groups (0.10 < p < 0.33). As shown in figure 2, AT-LPL expression was also similar in pre- and postmenopausal women, regardless of the fat depot (0.15 < p < 0.28). Both pre- and postmenopausal displayed reduced enzyme mRNA levels at the femoral site after walking (p < 0.01), but not at the abdominal level (p = 0.42).

Relationships between Changes in Adipose Tissue-Lipoprotein Lipase Activity and/or Expression and Lipid-Lipoprotein Metabolism
Reductions in the femoral AT-LPL activity or expression were associated neither with the slight reduction in plasma LDL cholesterol levels observed in all subjects (p < 0.05), whereas LDL cholesterol concentrations were reduced after walking in premenopausal women, exclusively (p < 0.05). Moreover, plasma estradiol levels remained unchanged after our intervention, in both groups.

Relationships between Adipose Tissue-Lipoprotein Lipase Activity and Expression
The extent of the fall in LPL activity observed after our intervention in the femoral (but not in the abdominal) fat depot was associated with the initial level of enzyme activity. Figure 3 shows that the higher was the initial femoral AT-LPL activity, the greater was its reduction when expressed per AT mass or per cell number in pre- and postmenopausal women considered together (−0.82 < r < −0.74; p < 0.0001). The decrease in femoral AT-LPL mRNA levels was also negatively related to the baseline enzyme expression (r = −0.56; p < 0.005). Changes in femoral AT-LPL expression were positively related to those in its activity when expressed per AT mass, only (r = 0.41; p < 0.05). However, there was no significant association between femoral AT-LPL mRNA levels and the enzyme activity assessed at baseline (−0.23 < r < −0.21). Similar data were observed at the abdominal site (not shown).
To the best of our knowledge, our study is the first to investigate the impact of aerobic exercise-induced weight loss on regional variation in AT-LPL activity and expression, after having carefully controlled for differences in women’s chronological cholesterol levels ($-0.34 < r < -0.26; 0.08 < p < 0.18$) nor with the modest decrease in HDL cholesterol concentrations ($-0.15 < r < -0.06; 0.46 < p < 0.77$) noted after our intervention. No significant relationship was found between changes in these lipid-lipoprotein variables and variation in the enzyme activity or expression assessed at the abdominal site (not shown).
ical age and obesity degree. Our results showed that the enzyme activity and its expression in the femoral (but not the abdominal) fat depot decreased similarly in response to our walking program, regardless of menopausal status.

The comparable fat cell size and AT-LPL activity noted in premenopausal women, irrespective of the region considered, is in contrast with previous [6, 7], but not all observations [5, 39]. Controversies between our findings and those of Rebuffé-Scrive et al. [7] could be due to the fact that the latter premenopausal women were younger (mean age of 30 ± 2 years), leaner (mean BMI of 23.7 ± 0.6 kg/m²) (mean ± SE) than our participants (table 2). Also, their AT-LPL activity was measured while women were either in the follicular or in the luteal phase of their menstrual cycle. Similarly, conflicting data between our study and the one of Raison et al. [6] could be attributed to differences in women’s age (38 ± 2 years) and obesity degree (35.2 ± 2 kg/m²), as well as to the fact that fat biopsies and LPL measurements were done during women’s luteal phase (i.e. between the 19th and 25th days of their menstrual cycle). In this regard, AT biopsies and enzyme assays were performed during the follicular phase of our subjects (i.e., between the 5th and 12th days of their menstrual cycle). Although the lack of regional variation in both fat cell weight and enzyme activity of postmenopausal women has largely been documented [7, 11–13, 39], it is not concordant with some studies [6, 9, 16] probably because of subjects’ fatness and age, duration of menopause, the use or not of HT, its mode of administration (oral vs. transdermal), as well as to the fact that estrogens were administered alone and/or combined with progesterone. In this regard, Rebuffé-Scrive et al. [11] and Lindberg et al. [13] clearly showed that HT was able to restore high fat cell size and AT-LPL activity in the femoral depot, when compared to the abdominal region. The fact that pre- and postmenopausal women had comparable fat cell size and AT-LPL activity is easily explainable by their physical characteristics at baseline (table 1), and concordant with previous reports [39, 40]. The lack of regional variation in AT-LPL mRNA abundance could also be partly explained by subjects’ fatness, as Arner et al. [14] already found higher LPL mRNA abundance in the gluteal than in the abdominal region of premenopausal non obese women. It is surprising that AT-LPL activity does not vary according to menopausal status, as plasma estradiol levels differ between pre- and postmenopausal women. However, no relationship was observed between the enzyme activity and plasma estradiol levels in the present study. In this regard, high estradiol levels were already shown to decrease abdominal AT-LPL activity while low doses had the opposite effects [41], although in vitro incubation of AT fragments with estradiol reduced the enzyme activity [42]. The use of whole AT fragments [42] instead of isolated adipocytes [41] could provide a valuable explanation for these conflicting data. Further experiments that will examine the influence of sex steroids on changes in AT-LPL activity with menopause transition are clearly warranted.

The fact that femoral (but not abdominal) AT-LPL activity was significantly reduced after walking, in the absence of reduced fat cell size and despite modest body weight and fat mass losses, could also be questioned. In this regard, attention should be paid to the preferential abdominal fat cell weight reduction reported after diet combined with aerobic exercise, in obese women [43]. Indeed, although gluteal adipocyte size decreased similarly in response to diet alone or associated with either low- or high-intensity exercise, subcutaneous abdominal fat size was preferentially reduced in combined weight loss interventions [43]. Moreover, the decrease in femoral AT-LPL activity noted after our 16-week walking program is concordant with previous reports [5, 15, 21, 44] but contrasts with others which showed a lack of change [10, 16, 17], or an increase in the enzyme activity [18–20]. Such discrepancy could be due to the substantial mean weight loss achieved reported in the 3 latter studies [18–20] or to subjects’ fatness, nature, and duration of the restrictive diet used to promote weight loss, combination of caloric restriction and aerobic exercise [10, 16, 17]. The negative relationship observed between the fall in LPL activity and the pre-weight loss enzyme activity has been frequently observed among studies reporting a decrease in AT-LPL activity [5, 15, 16, 21, 44]. Our results also revealed a reduction in femoral AT-LPL expression following endurance exercise, in both groups. Although this result is not in agreement with the similar post-weight loss enzyme expression reported by our group [5], such discrepancy could be due to the techniques used (Northern blot analysis versus RT-PCR) and/or to women’s age differences. In the present study, the higher the decrease in femoral AT-LPL expression, the greater the reduction in the enzyme activity, thus suggesting that changes may occur at a transcriptional level. However, as expression of LPL involves several steps such as gene transcription, processing, transport, and translation of mRNA as well as post-translational modifications, secretion, and extra-cellular activation of the enzyme [3] should be considered [14, 45]. Further studies measuring AT-LPL mass are needed to address this issue.

A decrease in AT-LPL activity after weight loss could lead to a reduction in TAG clearance, thus resulting in higher TAG as well as lower plasma HDL and LDL cholesterol concentrations. The lack of clear relationships between changes in plasma TAG levels and variation in AT-LPL activity has already been reported by us [5] and others [16], in pre- and postmenopausal women, respectively. In this regard, results of studies investigating the effect of caloric restriction combined with lipid-lowering drugs or exercise on plasma TG levels indicated that reductions in fasting TAG levels were associated with skeletal muscle rather than with AT-LPL activity [46]. On the other hand, we did not observe any association between variation in AT-LPL activity and changes in LDL and/or in HDL cholesterol levels, despite the slight reductions in these plasma lipoprotein levels after walking (table 3). This finding is in contrast with the positive relationship found be-
tween the decrease in femoral AT-LPL activity and the reduction in plasma HDL cholesterol concentrations after weight loss, already found in young premenopausal women by our group [5]. Although not statistically significant, similar trends for a decrease in plasma HDL cholesterol concentrations associated with a reduction in gluteal AT-LPL activity were already observed in postmenopausal women [16]. It is true that a high femoral or gluteal AT-LPL activity in pre- and postmenopausal women may increase the proportion of cholesterol ester remaining associated with HDL, the protective lipoprotein fraction against coronary heart disease [8, 12]. Therefore, the decrease in the femoral AT-LPL activity observed in our participants could be considered as deleterious from a clinical standpoint as HDL cholesterol concentrations were slightly reduced after walking. However, these values higher than the threshold defined by the NCEP-ATP III [35] still attested of a favourable lipid-lipoprotein profile. Finally, women whose abdominal and gluteal AT-LPL activities were reduced with weight loss regained less body weight at follow-up, thus suggesting that energy storage efficiency was decreased in the weight-reduced state of these women [16]. Regarding these findings, it should be thus hypothesized that weight regain will be less important in our participants.

Finally, the difference between groups of 7.7% in baseline HDL cholesterol levels, although being clinically marginal, reflected a favourable lipid-lipoprotein profile, as values recorded were above the threshold of 1.3 mmol/l defined by the NCEP/ATP III guidelines (2001) [35]. In addition, although waist girth values were above the NCEP-ATP III threshold, this criterion similarly decreased in all women, after our walking program. However, the fact that waist circumference was still higher than 88 cm, clearly attested of a subcutaneous abdominal rather than a visceral obesity [47]. Indeed, Lemieux et al. [48] have already proposed that the ‘hypertriglyceridemic waist’ (e.g. elevated waist circumference combined with high fasting TAG levels) should better identify individuals with an excessive visceral fat accumulation and the related features of metabolic syndrome. As plasma TAG levels were below the threshold of 1.7 mmol/l [35], our participants were probably characterized by a subcutaneous abdominal form of obesity, irrespective of their menopausal status.

Some limitations may, however, deserve further attention. Indeed, bioelectrical impedance was used to assess body composition instead of other methods more sophisticated such as DEXA. However, leg-to-leg bio-impedance has been validated during weight loss interventions conducted in overweight and obese individuals [49]. Estimated VO2 max was also extrapolated from the 2-km walking test (a sub-maximal exercise test), and some error should have thus been introduced as the equation used to predict VO2 max took into account variables such as elapsed time and HR at the end of a 2-km walk, and BMI [37]. However, the 2-km walking test was considered by the same group as a valid tool for predicting VO2 max changes after a 15-week walking program in middle-aged and healthy individuals [50]. On the other hand, reduction in fasting cholesterol levels could be probably considered as not clinically relevant, as the value reported (p = .049) was of borderline significance. Such findings could be partly explained by the small number of participants (n = 30). In this regard, the two sets of fat biopsies planned before and after our endurance exercise program represented an invasive intervention which may have limited the number of volunteers. Finally, although blood sample measurements should have been performed while premenopausal women were in the follicular phase of their menstrual cycle (e.g. between the 5th and the 12th days of their menstrual cycle), this was not possible because of our participants’ time constraints. Such an observation could provide an additional explanation to the wide range of variation observed in plasma HDL levels (table 3).

Our study also has several strengths such as the fact that women walked in indoor community facilities under the supervision of an exercise physiologist, 3 times per week, during which exercise intensity was continuously monitored through HR, and HR values were recorded in an exercise log book to ensure compliance with the training intensity. In addition, comparison of late pre- and early postmenopausal women with a narrow age difference allows better understanding of the effects of menopause on lipid storage capacities [40].

Conclusion

This study documents for the first time that both the LPL activity and mRNA level of the femoral (but not the subcutaneous abdominal) AT are similar, regardless of menopausal status, once chronological age and obesity degree are taken into account. Our 16-week walking program also seems to be sufficient to reduce lipid storage in the femoral fat depot of late pre- and early postmenopausal women. Finally, reduction in femoral AT-LPL activity does not lead to a more deleterious lipid-lipoprotein profile, despite the modest decrease observed in plasma HDL cholesterol levels.

Acknowledgements

This study was supported by the Canadian Institutes of Health Research (CIHR). The cooperation of subjects who participated to this walking program was greatly appreciated. We also gratefully thank Claude Leblanc for his statistical analyses. This study was supported by the operating grant # MOP-77572 obtained from CIHR. Thanks are also expressed to Alexandra Andersen, Denise Christen, Katie Lacasse, Geneviève Ouellet, Renaud Turcotte-Sabourin, Guillaume Salamin, and Jean Tremblay for their very helpful assistance in the supervision of walking sessions.

Disclosure

The authors declared no conflict of interest.
References


